BALAXI PHARMACEUTICALS DuPont analysis

·UnclassifiedChart ›

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.37×	0.27×	0.87×	−1.18×	0.81×
	1.00×	0.83×	0.81×	0.05×	1.04×
	2.3%	2.4%	12.1%	18.5%	16.3%
	0.83×	0.83×	1.03×	0.97×	1.62×
	1.35×	1.35×	1.34×	1.28×	1.31×
	1.0%	0.6%	11.8%	−1.2%	29.0%
	0.6%	0.6%	11.6%	−1.2%	31.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALAXI₹19.71

BALAXI PHARMACEUTICALS LIMITED

· Unclassified

₹ CrorePeersPAR STEELCITY LATTEYS CROWN HECPROJECT HINDCON AIROLAM GROBTEAMcap ₹109 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.81	-1.18	0.87	0.27	0.37
Interest Burden (Pretax/EBIT) ×	1.04	0.05	0.81	0.83	1.00
EBIT Margin %	16.28	18.50	12.07	2.36	2.32
Asset Turnover ×	1.62	0.97	1.03	0.83	0.83
Financial Leverage (Assets/Equity) ×	1.31	1.28	1.34	1.35	1.35
ROE (5-step product, year-end total equity) %	29.00	-1.23	11.82	0.59	0.97
ROE (owners' profit / average owners' equity) %	31.05	-1.24	11.58	0.59	0.59

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.